TCT 2014

 
 
 

The US Capitol building in Washington, DC.

TCT 2014, the Annual Scientific Symposium of the Cardiovascular Research Foundation, took place September 12-17 in Washington, DC.

 

Longer duration of triple therapy confers no benefit, trial suggests

HT Staff Read Article
Published: 09/19/14

aspirin_coated_Credit_Sage_Ross_230.jpg
Aspirin tablets
Credit: Sage Ross

Six weeks of triple anticoagulant therapy may be sufficient in patients who have received a drug-eluting stent. Results of the ISAR-TRIPLE trial revealed no significant differences in net clinical outcomes for patients who received 6 weeks of triple anticoagulant therapy and those who received 6 months of the therapy. Nikolaus Sarafoff, MD, of Deutsches Herzzentrum Munich and Klinikum der Universität Munich in Germany, presented these results at TCT 2014. [Read Article]

Bivalirudin bests heparin in BRIGHT trial

HT Staff Read Article
Published: 09/18/14

vials_chemo_drugs_Bill_Branson_230.jpg
Vials of drug
Credit: Bill Branson

New results from the BRIGHT trial suggest bivalirudin confers benefits over heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction undergoing percutaneous coronary intervention. Patients who received bivalirudin had a significantly lower incidence of net adverse clinical events (NACE), a composite of death from any cause, reinfarction, ischemia-driven target vessel revascularization, stroke, or any bleeding, both at 30 days and at 1 year. [Read Article]

Shorter duration of DAPT appears safe

HT Staff Read Article
Published: 09/18/14

thrombus_credit_Andre_E.X._Brown_230.jpg
Thrombus
Credit: Andre E.X. Brown

New research indicates that patients may only need 6 months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent. Results of the SECURITY trial showed that patients had similar outcomes whether they received DAPT for 6 months or a full year. The proportion of patients who met a composite endpoint of cardiac, thrombotic, and bleeding events was low among both treatment groups at the 12- and 24-month time points. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}